AntoXa’s growing portfolio of medical countermeasures addresses the need for effective therapeutics to protect against biological and chemical threats and infectious disease.
- The U.S. Strategic National Stockpile has been allocated USD$50 billion since 2001 to create a national repository of life-saving medical supplies including antitoxins.
- AntoXa has to date secured approximately CAD$4 million towards its medical countermeasure programs and is working with the Canadian, American and Australian departments of defence to prepare for a range of chemical and biological threats.
- Regulators give medical countermeasures a fast track to market and AntoXa is well-positioned to commercialize several products now in development.
- AntoXa’s products address key customer concerns regarding safety, cost and shelf-life.
To learn about investment opportunities, contact:
Don Stewart, CEO
1920 Yonge Street, Suite 200
Toronto, Ontario, Canada, M4S 3E2